SPY316.18+2.40 0.76%
DIA260.72+1.68 0.65%
IXIC10,492.50+148.61 1.44%

Needham Maintains Buy on Verrica Pharmaceuticals, Lowers Price Target to $17

Needham analyst Serge Belanger maintains Verrica Pharmaceuticals (NASDAQ:VRCA) with a Buy and lowers the price target from $20 to $17.

Benzinga · -
Needham analyst Serge Belanger maintains Verrica Pharmaceuticals (NASDAQ: VRCA) with a Buy and lowers the price target from $20 to $17.